Akebia Therapeutics to Participate in Upcoming Investor Conferences
17 November 2017 - 12:00AM
Business Wire
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical
company focused on delivering innovative therapies to patients with
kidney disease through the biology of hypoxia-inducible factor
(HIF), today announced that John P. Butler, President and Chief
Executive Officer, will participate in the following investor
conferences:
- The 29th Annual Piper Jaffray
Healthcare Conference on Wednesday, November 29, 2017, at 12:30
p.m. Eastern Time, to be held at the Lotte New York Palace in New
York, NY.
- The Evercore ISI Biopharma
Catalyst/Deep Dive Conference on Thursday, November 30, 2017, at
9:30 a.m. Eastern Time, to be held at the Boston Harbor Hotel in
Boston, MA.
- The Global Mizuho Investor Conference
on Tuesday, December 5, 2017, to be held at the Lotte New York
Palace in New York, NY.
A live audio webcast from the presentation at Piper Jaffray and
fireside chat at Evercore will be available on the Company’s
website at http://ir.akebia.com/events.cfm, with archives available
for 90 days.
About Akebia TherapeuticsAkebia Therapeutics,
Inc. is a biopharmaceutical company headquartered
in Cambridge, Massachusetts, focused on delivering innovative
therapies to patients with kidney disease through hypoxia-inducible
factor biology. Akebia’s lead product candidate, vadadustat, is an
oral, investigational therapy in development for the treatment of
anemia related to chronic kidney disease in both non-dialysis and
dialysis patients. Akebia’s global Phase 3 program for vadadustat,
which includes the PRO2TECT studies for non-dialysis patients with
anemia secondary to chronic kidney disease and the INNO2VATE
studies for dialysis-dependent patients, is currently ongoing. In
addition, the Company has initiated the Phase 2 FO2RWARD study of
vadadustat in dialysis-dependent chronic kidney disease patients
who are hyporesponsive to erythropoiesis-stimulating agents (ESAs),
and expects to commence the Phase 3 TRILO2GY study to further
evaluate a three-times-weekly dosing regimen for vadadustat. For
more information, please visit our website
at www.akebia.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171116005326/en/
Akebia TherapeuticsJohn Garabo, 617-844-6130Director,
Corporate Communicationsjgarabo@akebia.com
Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From Apr 2024 to May 2024
Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From May 2023 to May 2024